Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Korea.
Microb Drug Resist. 2011 Mar;17(1):37-45. doi: 10.1089/mdr.2010.0034. Epub 2010 Oct 17.
A total of 950 gram-negative bacterial isolates from patients with bacteremia and urinary tract infections were collected from tertiary-care hospitals in Korea. In vitro antimicrobial susceptibility testing was performed using broth microdilution test according to Clinical and Laboratory Standards Institute protocol. In general, carbapenems such as doripenem, imipenem, and meropenem were very active against Enterobacteriaceae, Moraxella catarrhalis, Pseudomonas aeruginosa, and Acinetobacter sp. isolates. Doripenem was more potent than imipenem against most Enterobacteriaceae species except Proteus spp. based on minimum inhibitory concentration (MIC)(50) and MIC(90). In addition, doripenem displayed similar activity to meropenem but was superior to imipenem against ceftazidime-resistant Enterobacteriaceae isolates. For P. aeruginosa and Acinetobacter spp. isolates, MIC(50)s of doripenem were 1 and 0.5 mg/L, respectively, which were the same with those of meropenem but two- to fourfold lower than those of imipenem (both 2 mg/L). On the basis of the in vitro data, we conclude that doripenem has equivalent or more activity than other carbapenems such as imipenem and meropenem against most gram-negative pathogens from Korea. Thus, doripenem may be a promising new antimicrobial agent for the treatment of infections caused by gram-negative pathogens in Korea.
共收集了来自韩国三家医院的 950 株革兰氏阴性菌分离株，这些分离株来自菌血症和尿路感染患者。根据临床和实验室标准协会的方案，采用肉汤微量稀释试验进行体外抗菌药敏试验。一般来说，多利培南、亚胺培南和美罗培南等碳青霉烯类药物对肠杆菌科、卡他莫拉菌、铜绿假单胞菌和不动杆菌属分离株非常有效。基于最低抑菌浓度（MIC）（50）和 MIC（90），多利培南对大多数肠杆菌科除变形杆菌属以外的细菌的活性均强于亚胺培南。此外，多利培南对头孢他啶耐药的肠杆菌科分离株的活性与美罗培南相似，但优于亚胺培南。对于铜绿假单胞菌和不动杆菌属分离株，多利培南的 MIC（50）分别为 1mg/L 和 0.5mg/L，与美罗培南相同，但比亚胺培南低两到四倍（均为 2mg/L）。根据体外数据，我们得出结论，多利培南对来自韩国的大多数革兰氏阴性病原体的活性与其他碳青霉烯类药物（如亚胺培南和美罗培南）相当或更强。因此，多利培南可能是治疗韩国革兰氏阴性病原体感染的一种有前途的新型抗菌药物。
